- Open Access
Evidence for biphasic uncoating during HIV-1 infection from a novel imaging assay
© Xu et al.; licensee BioMed Central Ltd. 2013
- Received: 2 May 2013
- Accepted: 5 July 2013
- Published: 9 July 2013
Uncoating of the HIV-1 core plays a critical role during early post-fusion stages of infection but is poorly understood. Microscopy-based assays are unable to easily distinguish between intact and partially uncoated viral cores.
In this study, we used 5-ethynyl uridine (EU) to label viral-associated RNA during HIV production. At early time points after infection with EU-labeled virions, the viral-associated RNA was stained with an EU-specific dye and was detected by confocal microscopy together with viral proteins. We observed that detection of the viral-associated RNA was specific for EU-labeled virions, was detected only after viral fusion with target cells, and occurred after an initial opening of the core. In vitro staining of cores showed that the opening of the core allowed the small molecule dye, but not RNase A or antibodies, inside. Also, staining of the viral-associated RNA, which is co-localized with nucleocapsid, decays over time after viral infection. The decay rate of RNA staining is dependent on capsid (CA) stability, which was altered by CA mutations or a small molecule inducer of HIV-1 uncoating. While the staining of EU-labeled RNA was not affected by inhibition of reverse transcription, the kinetics of core opening of different CA mutants correlated with initiation of reverse transcription. Analysis of the E45A CA mutant suggests that initial core opening is independent of complete capsid disassembly.
Taken together, our results establish a novel RNA accessibility-based assay that detects an early event in HIV-1 uncoating and can be used to further define this process.
- Reverse Transcript
- Cell Extraction Buffer
- Reverse Transcription Complex
- TRIMCyp Restriction
- Uncoating Step
The replication cycle of HIV-1 is complex; while many of the critical steps have been described in great detail, some, including uncoating of the viral core, remain poorly understood. After fusion with the host cell, HIV-1 releases the core into the cytoplasm. The core contains the conical viral capsid, composed of a polymer of capsid protein (CA) subunits, encasing the viral RNA (vRNA) genome. The viral RNA undergoes reverse transcription, forming viral DNA (vDNA) in the cytoplasm. The vDNA together with the nucleocapsid (NC), reverse transcriptase (RT), Vpr, and integrase (IN) form the pre-integration complex (PIC). The PIC is transported to the nucleus by way of microtubules and actin filaments in the cytoplasm [1, 2], and subsequently enters the nucleus by mechanisms which have only recently begun to be examined in detail . Inside the nucleus, the HIV-1 DNA is integrated into host cell chromatin, after which the provirus is transcribed for viral protein expression for particle assembly and release from the cell.
The stability of the HIV-1 capsid has been linked to reverse transcription and nuclear entry. CA mutations that alter the intrinsic stability of the capsid have profound effects on reverse transcription  and entry of viral DNA into the nucleus [5–8]. In addition, the rhesus macaque tripartite interaction motif 5α protein (rhTRIM5α) is a restriction factor that inhibits HIV-1 and other retroviruses by targeting the viral capsid and inhibiting reverse transcription , likely by perturbing the capsid structure. Proteasome inhibitors relieve the block to reverse transcription by rhTRIM5α, suggesting that this restriction targets the reverse transcription complex (RTC) for proteasomal degradation . In addition, the RTC requires cellular factors for completion of reverse transcription that are independent of CA mutations that alter core stability [11, 12]. Despite the importance of the structure and stability of the viral capsid in HIV-1 infection, the process of uncoating, which we define as dissociation of the capsid from the core, remains poorly understood, mainly owing to difficulties in the detection of HIV-1 cores soon after entry into target cells. A recent study described the development of assays measuring association of HIV-1 Vpr and CA in HeLa cells, and the timing of escape from TRIMCyp-mediated restriction in owl monkey cells. Using these novel approaches, the authors reported that uncoating could be delayed for a virus with a hyperstable capsid or by preventing reverse transcription, further reinforcing the functional connection between HIV-1 uncoating and reverse transcription .
Despite recent advances in studies of the structure and stability of the HIV-1 capsid, uncoating remains poorly understood and is not currently possible to study by live-cell imaging techniques due to lack of available methods to label CA molecules without perturbing the function of the viral capsid. Fluorescence microscopic methods to track the core and viral protein or DNA components of the RTC/PIC have been employed previously [1, 2, 14–16], but are limited in terms of sensitivity. To circumvent these problems, we applied an alternative method of labeling HIV-1 RNA such that it could be stained with a fluorescent small molecule dye after capsid dissociation in vitro or during cell infection. The dye is specific for virus particle-associated RNA and can only access the viral nucleic acid after an initial uncoating step that appears to involve opening of the capsid. We observed that the kinetics of RNA staining were altered by the presence of rhTRIM5α or TRIMCyp, by CA substitutions altering capsid stability, and by addition of a small molecule inducer of HIV-1 uncoating. Surprisingly, the previously identified E45A CA mutant, which exhibits hyperstable cores in vitro, exhibited efficient staining of viral-associated RNA through cores in vitro and accelerated staining kinetics in vivo, suggestive of a permeable capsid.
HIV-1 RNA staining in virions requires CA core opening
To label and track HIV-1 RNA intracellularly, we incorporated a modified nucleoside, 5-ethynyl uridine (EU), into vRNA during virus production. Detection of alkyne-modified nucleosides in vRNA was performed by selective ligation of an azide-containing fluorescent dye to the modified nucleoside, in a so-called a “click” reaction , and subsequent fluorescent confocal microscopy of infected target cells. Because HIV-1 particles can incorporate cellular mRNA from the producer cell [18–20], the modified virus-associated RNA could, in principle, be both cellular and viral in origin.
Specific infectivity (infectious units per ng p24) of EU-labeled viruses
p24 (ng/ml) ± SD
191 ± 3
EU for 1st 16 h
28 ± 4
EU for 2nd 24 h
165 ± 4
EU for 48 h
20 ± 1
107 ± 10
Labeled HIV-1 RNA is detected in infected cells
To determine whether or not virus-associated RNA staining detected HIV-1 prior to fusion and entry into cells, virus was produced in the presence of EU and the membrane-associated S15-Cherry protein . Thus, vRNA was labeled with EU (green) and viral membranes were labeled with S15-mCherry (red). A loss of mCherry signal indicates that virus particles have fused with the cell or endosomal membrane. S15-mCherry was efficiently incorporated into virions as shown in particles containing a packagable viral genome with binding sites for the bacteriophage MS2 protein and produced in cells expressing MS2-GFP fusion protein (Figure 2B). When EU- and mCherry-labeled particles were added to cells, some mCherry particles on or between cells were observed even after extensive washing. However, vRNA staining was not co-localized with mCherry in any fields, suggesting that the EU staining was specific for intracellular virus-associated RNA. This was expected, as the dye does not permeate through lipid bilayers, including viral membranes.
Labeled HIV-1 RNA maintains co-localization with NC but not Vpr or CA after infection
HIV-1 nucleocapsid (NC) has been shown to bind vRNA and act as a chaperone during vDNA synthesis . Therefore, vRNA should remain associated with NC in the core and throughout reverse transcription after uncoating. To determine if EU-labeled vRNA was co-localized with NC, staining for NC by monoclonal antibodies together with EU staining was performed in HIV-1 infected cells (Figure 3B). While NC and GFP-Vpr could be detected alone, vRNA staining was co-localized with NC much more than with GFP-Vpr or CA at 1 h post-infection. NC and vRNA co-localization occurred 71% after 15 minutes and 66% after 1 h post-infection (Figure 4A), suggesting that EU detection was specific for virus-associated RNA. By contrast to GFP-Vpr and CA, NC detection did not diminish over time in the infected cells, suggesting that the particles were not being totally degraded (Figure 4B).
Intracellular HIV-1 RNA staining increases within 30 minutes post-infection and is affected by rhTRIM5α and TRIMCyp
rhTRIM5α has been shown to bind to HIV-1 capsids and to restrict HIV-1 infection prior to reverse transcription in vivo [9, 28]. This restriction factor has also been reported to disrupt HIV-1 cores and assembled CA tubes in vitro [21–23]. We therefore examined the effects of rhTRIM5α on the kinetics of staining of virus-associated RNA. When cells expressing rhTRIM5α were infected with EU-labeled viruses, we observed a small initial increase in the number of detectable vRNA between 15 – 25 min post-infection that decreased rapidly, and the low level of staining remained fairly stable during the time course of up to 270 minutes (Figure 5A). This difference compared to normal TZM-bl cells may be due to more rapid and complete disruption of the incoming CA cores by the restriction factor, allowing the stain to access vRNA earlier.
Similarly, owl monkey kidney (OMK) cells express TRIMCyp, a fusion protein of TRIM5α and cyclophilin A, that restricts HIV-1 infection and can be reversed by inhibiting TRIMCyp binding to CA with the drug cyclosporine A (CsA) [29, 30]. OMK cells were infected with EU-labeled WT HIV-1 and stained for RNA between 15 – 90 minutes post-infection (Figure 5B). Like cells expressing rhTRIM5α, these cells expressing TRIMCyp did not show an early increase in RNA staining. This staining pattern was reversed in cells treated with CsA, suggesting that when the TRIMCyp restriction was relieved, there was a delay in vRNA staining owing to restoration of normal uncoating.
The RNase H activity of RT cleaves the vRNA in RNA-DNA hybrids formed during reverse transcription, and we wondered whether RNase H-dependent degradation is responsible for the observed decrease in vRNA staining over time. To test this, we made EU-labeled HIV-1 containing the D443N amino acid substitution in RT. This mutant leads to a loss of RNase H activity, leading to incomplete reverse transcription . As a result, this mutant had almost a 190-fold decrease in specific infectivity as compared to WT HIV-1 (Table 1), despite having similar levels of viral particles. The vRNA staining assay revealed that D443N HIV-1 had a similar decay curve as WT HIV-1 in TZM-bl cells (Figure 5C), indicating that vRNA degradation was not due to viral RNase H activity. These results also indicated that premature termination of reverse transcription does not alter the kinetics of vRNA staining.
Perturbation of HIV-1 CA capsid stability by mutations or a drug alters vRNA staining kinetics
Interestingly, E45A HIV-1, which had previously been described as having a hyperstable capsid and lower infectivity as compared to WT HIV-1 [4, 33], exhibited a rapid vRNA decay profile that was similar to that of K203A. However, unlike the K203A mutant, E45A HIV-1 had an increase in vRNA staining between 15 – 25 minutes post-infection, followed by a significant decline at 35 minutes post-infection (Figure 6A). These data indicate that the capsid of E45A HIV-1 dissociated early after infection. The E45A phenotype was partially reversed with the addition of the mutation of R132T, resulting in a double mutant for which EU staining resembled WT HIV-1. The E45A/R132T mutant is more infectious than the E45A mutant, indicating that the functional defect induced by E45A is partially rescued by R132T .
To further examine whether capsid stability affects the kinetics of vRNA decay, we tested the effect of PF74, a small molecule inhibitor that destabilizes the HIV-1 capsid [32, 35], in our assay (Figure 6B). We infected TZM-bl cells with WT HIV-1 in the presence of PF74 and observed accelerated vRNA decay relative to infection in the absence of the compound. Whereas WT vRNA staining began to decay after 45 minutes post-infection in untreated cells, PF74 led to lower vRNA staining at the first time point, showing no transient increase in vRNA staining that is observed with most viruses in cells without the CA inhibitor, similar to the unstable K203A mutant. In contrast, the PF74-resistant 5Mut virus  was efficiently stained with the EU dye for extended times, and its staining was unaffected by infection in the presence of PF74.
CA E45A HIV-1 cores are more permeable than WT HIV-1 cores
One aspect of HIV-1 biology that is just beginning to be understood is the process of uncoating of the core following viral entry into the cell. Uncoating appears intimately linked to reverse transcription, as mutations that destabilize the capsid generally impair reverse transcription in target cells , as do restrictive TRIM5 proteins [9, 37]. Completion of reverse transcription may also require capsid dissociation, allowing the RTC to come into contact with putative positive-acting intracellular factors that facilitate viral DNA synthesis [11, 12]. Reverse transcription may also promote later stages of uncoating; perhaps the size and rigidity of double-stranded viral DNA formed during reverse transcription may help to destabilize the CA lattice and may not physically fit inside of the core . However, a structural and molecular understanding of uncoating and its role in reverse transcription remain unresolved.
In the present study, we describe the detection of intracellular HIV-associated RNA during infection. The modified nucleoside, EU, is incorporated into viral and cellular RNA in the producer cell. Fluorescent azide molecules can efficiently and selectively engage RNA-incorporated EU in a “click” reaction after entry into the CA core. We did not observe significant background staining of uninfected cells or cells infected with unlabeled HIV-1. Neither the virus-associated RNA signal nor the decay of this signal required reverse transcription or viral RNase H activity, which may be the result of a loss of signal of the labeled RNA after dissociation of the CA core and diffusion in the cytosol. The EU signal persisted for up to 4 hours, but the staining became more diffuse over time. vRNA was largely associated with NC but less so with CA or GFP-Vpr, especially as the infection progressed. This was not surprising, since HIV-1 NC favors binding to single-stranded RNA and assists RT with various steps during reverse transcription [27, 38]. In contrast, CA has been shown previously to dissociate within 40–60 minutes post-infection, and over 50% of the GFP-Vpr signal is lost between 1 and 2 hours post-infection , which is consistent with our results.
Our assay showed a steady, reproducible loss of HIV-1 RNA detection with time, consistent with uncoating and the proposed instability of HIV-1 RNA in the cytosol . The kinetics were affected by manipulating capsid stability by mutations or a small molecule CA inhibitor. The K203A CA mutant, which has been described as having a more fragile core than WT [4, 13], showed more rapid loss of vRNA staining. Similarly, cells infected with WT HIV-1 that were treated with PF74, a capsid-destabilizing compound , showed much more rapid vRNA decay than in untreated cells. Conversely, the 5Mut CA mutant that has a very stable core  had more persistent detection of EU-labeled RNA that did not decline appreciably for up to 75 minutes post-infection and did not show vDNA accumulation during that time period. 5Mut particles are resistant to PF74 antiviral action and capsid destabilization, which explains the similar vRNA staining that we observed for this virus in the presence and absence of the drug. Interestingly, the infectivity of 5Mut particles is similar to WT , suggesting that a hyperstable capsid is not an impediment to HIV-1 infection, at least in some target cells.
While it seems likely that the decay of HIV-1 CA staining in HeLa cells over time also reflects uncoating, as shown recently , its rapid decline and loss of signal (t1/2 of approximately 1–2 hours post-infection) suggests that the immunochemical assay is detecting a major uncoating event in which most CA molecules disassociate from the RTC within 1 hour post-infection. Due to the difficulty in obtaining reproducible staining quantitation of sufficient number of particles, the CA staining assay lacks the requisite sensitivity to identify subtle changes in capsid structure and the extent of uncoating. By contrast, the EU staining assay relies on RNA accessibility to a small molecule dye, and the rapid increase in staining observed for wild type HIV-1 suggests that RNA cannot be accessed by the dye until an initial event occurs in the presence of cellular factors. This was evident when looking at infection of cells between 15 – 45 minutes post-infection with WT HIV-1 and different CA mutants, and in biochemical studies with permeabilized virions. We also observed an increase in detection of NC, which should be contained within the core, between 30 and 75 minutes after infection. This initial opening did not lead to an immediate loss of CA staining, suggesting that EU staining reflects a more subtle uncoating step occurring prior to bulk dissociation of CA from the core. We also detected cellular accumulation of vDNA only after 75 minutes of virus inoculation, suggesting that reverse transcription proceeds after access to the cytosol.
The putative early uncoating event reflected by RNA staining also appeared to be inhibited by rhTRIM5α and TRIMCyp restriction factors. rhTRIM5α engages the capsid prior to reverse transcription and binds to assembled capsids, leading to their disruption [9, 21, 23, 28]. Similarly, TRIMCyp leads to capsid disassembly that is prevented by CsA treatment [29, 30]. Our RNA accessibility assay results are consistent with the interpretation that these restriction factors disrupt the HIV-1 capsid and the effects of TRIMCyp restriction on vRNA staining could be reversed by CsA treatment, which prevents restriction.
Previously, Hulme et al. showed that complete uncoating, as measured by GFP-Vpr and CA co-localization, or by escape from TRIMCyp by timed CsA withdrawal , is delayed by treatment by an RT inhibitor, suggesting that reverse transcription promotes uncoating. Our results showed that inhibition of reverse transcription did not alter the kinetics of RNA accessibility, suggesting that the early uncoating event required for RNA exposure is not dependent on reverse transcription and consistent with a recent study showing the fate of viral core components during premature uncoating . It is possible that human cell factors induce an initial uncoating event to allow reverse transcription to continue such that complete dissociation of the core can occur. It is also possible that the early uncoating event results in permeabilization of the core to small molecules, such as dNTPs, required for reverse transcription.
It was surprising that the E45A mutant, which was described as having a more stable capsid than WT HIV-1 , consistently exhibited RNA accessibility kinetics that resembled those of mutants with unstable capsids. In contrast to the K203A mutant, cytoplasmic E45A cores initially exhibited a small transient increase in RNA staining between 15 and 25 minutes post-infection, similar to WT cores. This was followed by a rapid decrease in vRNA staining as observed for the unstable K203A mutant. Furthermore, reverse transcription was initiated more rapidly for E45A HIV-1 as compared to WT HIV-1 or the other mutants tested. Importantly, the second-site suppressor mutation, R132T, partially restored the E45A RNA staining kinetics to wild type, correlating the effect of E45A mutation on RNA accessibility with its impairment of infectivity. Our previous results using correlative live-cell microscopy and cryo-electron tomography of infected cells suggested that E45A CA cores disassociate more slowly intracellularly than WT cores . While the comparable behavior of the K203A and E45A mutants appears contradictory, it supports the hypothesis that a subtle HIV-1 CA uncoating event precedes and is independent of a more extensive dissociation of CA from the core. We suggest that for the E45A mutant virus, the first uncoating step occurs more rapidly than for WT HIV-1 but that the second uncoating step is delayed relative to WT HIV-1. The first step would allow an opening for some cellular factors to access the interior of the core, leading to more rapid synthesis of early reverse transcripts, consistent with the results shown here. However, the majority of the E45A CA remains intact, delaying completion of reverse transcription as compared to WT HIV-1. It is possible that a multi-step uncoating process is necessary for both HIV-1 to complete reverse transcription with cellular factors and allowing the RTC to be somewhat contained to prevent disassociation of key components from the complex. Consistently biphasic uncoating of purified HIV-1 cores has been observed biochemically . Alternatively, the lattice of E45A CA cores may be more leaky, allowing small molecules to gain access inside. Further high-resolution studies comparing WT and E45A CA cores are needed to determine if they differ in lattice structure or flexibility.
In conclusion, we have developed a fluorescence-based RNA accessibility assay that detects an initial opening of the HIV-1 capsid. This initial uncoating step may be triggered by host cell factors and can be influenced by alteration of the stability of the core by CA mutations or a small molecule inhibitor. The RNA accessibility assay, in combination with complementary approaches to detect capsid dissociation, will be useful for studying the role of cellular factors in the early postentry stages of HIV-1 infection.
Cell lines and antiviral compounds
293T cells were used for transfections and for cell lysates described in assays below. TZM-bl cells are HeLa cells expressing CD4, CXCR4, and CCR5 that carry the lacZ and firefly luciferase genes downstream from the HIV-1 LTR . OMK cells are owl monkey kidney cells that have been shown to express endogenous TRIMCyp [29, 30]. TZM-rhTRIM5α and 293T-rhTRIM5α cells express rhTRIM5α from the pLPCX-TRIM5a-HA vector, obtained through the NIH AIDS Research and Reference Reagent Program from Drs. Joseph Sodroski and Matt Stremlau. GHOST cells are human osteosarcoma cells expressing CD4, CXCR4, and CCR5 that carry the GFP gene downstream from the HIV-2 LTR . All cells were grown in DMEM and supplemented with 10% fetal bovine serum and 1% penicillin, streptomycin, and L-glutamine. PF-3450074 (PF74)  was synthesized by the Vanderbilt Institute of Chemical Biology Synthesis Core, Vanderbilt University, Nashville, TN. PF74 was dissolved as a 10 mM stock in DMSO and added to target cell cultures at a final concentration of 10 μM.
Virus stocks and EU-incorporation
HIV-1 particles were made by transfection of 293T cells with the following plasmids: pNLdVdE-luc, a plasmid containing the HIV-1NL4-3 provirus with an early stop codon in vpr, a deletion in env, and the firefly luciferase gene in place of nef ; GFP-Vpr plasmid, a kind gift from Dr. Tom Hope ; and pL-VSV-G, a plasmid encoding the envelope glycoprotein from vesicular stomatitis virus (VSV) . Particles were also produced with the S15-mCherry plasmid, a kind gift from Dr. Tom Hope . The pNLdVdE-luc plasmid had the following CA amino acid substitutions introduced by via cloning from other HIV-1NL4-3 vectors or PCR mutagenesis: E45A, E45A/R132T, K203A, or 5Mut. Similarly, PCR mutagenesis was used to create pNLdVdE-luc containing the RT mutation D443N. Transfections were performed using calcium phosphate or Lipofectamine 2000 in medium containing 0.1 – 1 mM EU (Invitrogen, Carlsbad, CA) for 48 h. Cell supernatants were collected, ultracentrifuged through a 20% sucrose cushion to remove free EU, resuspended in fresh medium, and frozen at −80°C in aliquots.
Viruses from transfection supernatants were titered in GHOST cells in duplicate. Medium was replaced after 2 h and cells were analyzed after 48 h on an LSRII flow cytometer for GFP expression in <40% of the cells. CA levels were measured by serial dilutions of supernatants by p24 ELISA (Zeptometrix, Buffalo, NY) in duplicate.
Additional experiments showing EU co-localization with virus containing bacteriophage MS2 coat protein binding sites were performed, using a plasmid encoding a viral vector sequence containing twelve MS2-binding sites. The vector was cotransfected with either WT or E45A pcHelpΔVif , a kind gift from Dr. Klaus Strebel, pL-VSV-G, and pcDNA-MS2GFP, a vector expressing MS2-GFP, in the presence of 0.4 mM EU. The transfection medium was replaced with 0.1 mM EU an additional 32 h. The EU-labeled virions were harvested by filtering through 0.45 μm syringe filters and purified through a sucrose cushion. The pelleted virions were resuspended in 200 μl of fresh DMEM medium with 50% FBS and subjected to imaging analysis. Viruses were quantified by p24 ELISA.
Viral RNA labeling and viral protein staining in cells
TZM-bl or TZM-rhTRIM5α cells were plated in 8-well chamber slides and virus was added at 4°C at equal multiplicities of infection or p24 levels for 30 minutes to synchronize infections. OMK cells were plated in chamber slides in the presence or absence of 10 μM CsA (Bedford Laboratories, Bedford, OH). Cells were transferred to 37°C thereafter for 15 or 30 minutes. Cells were washed twice with fresh medium and incubated at 37°C for up to 360 minutes. Cells were fixed in 2% paraformaldehyde (PFA) for 15 minutes, washed with PBS twice, and permeabilized with 0.05% Triton X in PBS for 15 minutes. The cells were stained with the Click-iT RNA Imaging Kit with Alexa Fluor 488 or Alexa Fluor 594 (Invitrogen) as per the manufacturer’s instructions. Staining with anti-CA monoclonal antibody (AG3.0), obtained through the NIH AIDS Research and Reference Reagent Program from Dr. Jonathan Allan , and anti-NC monoclonal antibodies, a kind gift from Dr. Robert Gorelick, was performed, followed by staining with anti-mouse IgG-Cy5. Imaging was performed using an Olympus Fluoview 1000–1 confocal microscope. RNA and viral protein puncta were enumerated by Imaris software.
Viral RNA labeling in viral particles
EU-labeled HIV particles were treated with cell extraction buffer (100 mM sodium chloride, 10 mM Tris pH 7.5, 1 mM EDTA, 0.5% Triton X-100, 10% glycerol, 1 μg/ml pepstatin, 1 μg/ml aprotinin, 1 μg/ml leupeptin and 1 mM sodium peroxyvanadate) alone or cell lysates of 293T cells or 293T-rhTRIM5α cells (2 x107 cells/ml of cell extraction buffer) for 30 minutes in the presence or absence of RNase A at room temperature. HIV-1 particles were fixed with 2% paraformaldehyde in 8-well chambered #1.0 borosilicate coverglass (Lab-Tek, Scotts Valley, CA) coated with Cell-Tak (BD Biosciences, San Jose, CA). The wells were treated with PBS containing 0.05% Triton-X-100 (Fisher Scientific, Pittsburgh, PA) for 15 minutes and washed with PBS once. vRNA was stained by the Click-iT RNA Imaging Kit per the manufacturer’s instructions and washed 5 times in PBS before mounting. Imaging was performed using an Olympus Fluoview 1000–1 Confocal Microscope and staining was enumerated using Imaris.
qPCR for viral DNA
Viruses were treated with DNase I (60 units/ml) for 30 minutes at 37°C. To control for any contaminating plasmid carry-over, the plasmid pEGFP-C1 (Clontech, Mountain View, CA), which does not encode any retroviral sequences, was added to the virus prior to infection (6 × 1010 copies). TZM-bl cells were incubated with equal amounts of virus particles (5 ng CA per well) for 30 minutes at 4°C. Controls for each virus infected in the presence of 150 nM of efavirenz was included. After incubation, virus was removed and fresh medium was added. Cells were switched to 37°C for further incubation of 15 min. The plates were washed and incubated for different lengths of time. Cells were lysed with cell extraction buffer, mixed with phenol, and stored on ice. Cellular DNA was purified by phenol-chloroform extraction and ethanol precipitation. vDNA quantification by real time PCR could be affected by variations from multiple steps, including adding virus, removing virus, washing after infection, cell lysing, DNA purification and PCR sample loading. To minimize the variation in vDNA quantification, we used two primer sets in each PCR reaction to detect both reverse transcripts and internal pEGFP-C1 plasmid. The HIV-1 primers and probes used were previously described, using FAM/TAMRA . The eGFP primers used were 5’-tacgtccaggagcgcaccat-3’ (forward) and 5’-cagctcgatgcggttcacca-3’ (reverse) and the probe was 5’-HEX-acgacggcaactacaagacc-IBFQ-3’. We used a single plasmid, pHIV-eGFP  (a kind gift from P. Bieniasz) with both HIV and GFP control sequences as the standard. After qPCR, reverse transcript levels were normalized by internal control and any background in the presence of efavirenz was subtracted, typically 2-4% of the levels measured in the absence of drug.
Paired two-sided student’s t tests were performed to compare puncta counts for different viral RNA or proteins, viruses, or treatment conditions at individual time points using Prism (GraphPad Software, La Jolla, CA), with the exception of comparisons of reverse transcript results which used an unpaired student’s t test of the duplicates.
We thank Dr. Paul Bieniasz, Dr. Rob Gorelick, Dr. Tom Hope, Dr. Klaus Strebel, and the NIH AIDS Research & Reference Reagent Program, Division of AIDS, NIAID, NIH for valuable reagents, and Kwangho Kim for synthesis of PF74. We also thank Dr. Vineet KewalRamani for helpful discussions. This work is a contribution from the Pittsburgh Center for HIV Interactions and was supported by the National Institutes of Health grants GM082251 (S.W., C.A., Z.A.), GM068406 (N.S.-C.) and AI089401 (C.A.).
- Arhel N, Genovesio A, Kim KA, Miko S, Perret E, Olivo-Marin JC, Shorte S, Charneau P: Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nat Methods. 2006, 3: 817-824. 10.1038/nmeth928.View ArticlePubMedGoogle Scholar
- McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ: Visualization of the intracellular behavior of HIV in living cells. J Cell Biol. 2002, 159: 441-452. 10.1083/jcb.200203150.PubMed CentralView ArticlePubMedGoogle Scholar
- Levin A, Loyter A, Bukrinsky M: Strategies to inhibit viral protein nuclear import: HIV-1 as a target. Biochim Biophys Acta. 1813, 2011: 1646-1653.Google Scholar
- Forshey BM, von Schwedler U, Sundquist WI, Aiken C: Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J Virol. 2002, 76: 5667-5677. 10.1128/JVI.76.11.5667-5677.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Dismuke DJ, Aiken C: Evidence for a functional link between uncoating of the human immunodeficiency virus type 1 core and nuclear import of the viral preintegration complex. J Virol. 2006, 80: 3712-3720. 10.1128/JVI.80.8.3712-3720.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Lee K, Ambrose Z, Martin TD, Oztop I, Mulky A, Julias JG, Vandegraaff N, Baumann JG, Wang R, Yuen W, et al: Flexible use of nuclear import pathways by HIV-1. Cell Host Microbe. 2010, 7: 221-233. 10.1016/j.chom.2010.02.007.PubMed CentralView ArticlePubMedGoogle Scholar
- Yamashita M, Emerman M: Capsid is a dominant determinant of retrovirus infectivity in nondividing cells. J Virol. 2004, 78: 5670-5678. 10.1128/JVI.78.11.5670-5678.2004.PubMed CentralView ArticlePubMedGoogle Scholar
- Yamashita M, Perez O, Hope TJ, Emerman M: Evidence for direct involvement of the capsid protein in HIV infection of nondividing cells. PLoS Pathog. 2007, 3: 1502-1510.View ArticlePubMedGoogle Scholar
- Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature. 2004, 427: 848-853. 10.1038/nature02343.View ArticlePubMedGoogle Scholar
- Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ: Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proc Natl Acad Sci U S A. 2006, 103: 7465-7470. 10.1073/pnas.0510483103.PubMed CentralView ArticlePubMedGoogle Scholar
- Warrilow D, Stenzel D, Harrich D: Isolated HIV-1 core is active for reverse transcription. Retrovirology. 2007, 4: 77-10.1186/1742-4690-4-77.PubMed CentralView ArticlePubMedGoogle Scholar
- Warrilow D, Warren K, Harrich D: Strand transfer and elongation of HIV-1 reverse transcription is facilitated by cell factors in vitro. PLoS One. 2010, 5: e13229-10.1371/journal.pone.0013229.PubMed CentralView ArticlePubMedGoogle Scholar
- Hulme AE, Perez O, Hope TJ: Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci U S A. 2011, 108: 9975-9980. 10.1073/pnas.1014522108.PubMed CentralView ArticlePubMedGoogle Scholar
- Albanese A, Arosio D, Terreni M, Cereseto A: HIV-1 pre-integration complexes selectively target decondensed chromatin in the nuclear periphery. PLoS One. 2008, 3: e2413-10.1371/journal.pone.0002413.PubMed CentralView ArticlePubMedGoogle Scholar
- Arhel NJ, Souquere-Besse S, Munier S, Souque P, Guadagnini S, Rutherford S, Prevost MC, Allen TD, Charneau P: HIV-1 DNA Flap formation promotes uncoating of the pre-integration complex at the nuclear pore. EMBO J. 2007, 26: 3025-3037. 10.1038/sj.emboj.7601740.PubMed CentralView ArticlePubMedGoogle Scholar
- Campbell EM, Perez O, Anderson JL, Hope TJ: Visualization of a proteasome-independent intermediate during restriction of HIV-1 by rhesus TRIM5alpha. J Cell Biol. 2008, 180: 549-561. 10.1083/jcb.200706154.PubMed CentralView ArticlePubMedGoogle Scholar
- Jao CY, Salic A: Exploring RNA transcription and turnover in vivo by using click chemistry. Proc Natl Acad Sci U S A. 2008, 105: 15779-15784. 10.1073/pnas.0808480105.PubMed CentralView ArticlePubMedGoogle Scholar
- Onafuwa-Nuga AA, Telesnitsky A, King SR: 7SL RNA, but not the 54-kd signal recognition particle protein, is an abundant component of both infectious HIV-1 and minimal virus-like particles. RNA (New York, NY). 2006, 12: 542-546. 10.1261/rna.2306306.View ArticleGoogle Scholar
- Rulli SJ, Hibbert CS, Mirro J, Pederson T, Biswal S, Rein A: Selective and nonselective packaging of cellular RNAs in retrovirus particles. J Virol. 2007, 81: 6623-6631. 10.1128/JVI.02833-06.PubMed CentralView ArticlePubMedGoogle Scholar
- Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK: Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem. 2004, 279: 35822-35828. 10.1074/jbc.M405761200.View ArticlePubMedGoogle Scholar
- Black LR, Aiken C: TRIM5alpha disrupts the structure of assembled HIV-1 capsid complexes in vitro. J Virol. 2010, 84: 6564-6569. 10.1128/JVI.00210-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Langelier CR, Sandrin V, Eckert DM, Christensen DE, Chandrasekaran V, Alam SL, Aiken C, Olsen JC, Kar AK, Sodroski JG, Sundquist WI: Biochemical characterization of a recombinant TRIM5alpha protein that restricts human immunodeficiency virus type 1 replication. J Virol. 2008, 82: 11682-11694. 10.1128/JVI.01562-08.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhao G, Ke D, Vu T, Ahn J, Shah VB, Yang R, Aiken C, Charlton LM, Gronenborn AM, Zhang P: Rhesus TRIM5alpha disrupts the HIV-1 capsid at the inter-hexamer interfaces. PLoS Pathog. 2011, 7: e1002009-10.1371/journal.ppat.1002009.PubMed CentralView ArticlePubMedGoogle Scholar
- Dahlberg JE: Quantitative electron microscopic analysis of the penetration of VSV into L cells. Virology. 1974, 58: 250-262. 10.1016/0042-6822(74)90159-7.View ArticlePubMedGoogle Scholar
- Fan DP, Sefton BM: The entry into host cells of Sindbis virus, vesicular stomatitis virus and Sendai virus. Cell. 1978, 15: 985-992. 10.1016/0092-8674(78)90282-9.View ArticlePubMedGoogle Scholar
- Campbell EM, Perez O, Melar M, Hope TJ: Labeling HIV-1 virions with two fluorescent proteins allows identification of virions that have productively entered the target cell. Virology. 2007, 360: 286-293. 10.1016/j.virol.2006.10.025.PubMed CentralView ArticlePubMedGoogle Scholar
- Levin JG, Guo J, Rouzina I, Musier-Forsyth K: Nucleic acid chaperone activity of HIV-1 nucleocapsid protein: critical role in reverse transcription and molecular mechanism. Prog Nucleic Acid Res Mol Biol. 2005, 80: 217-286.View ArticlePubMedGoogle Scholar
- Ganser-Pornillos BK, Chandrasekaran V, Pornillos O, Sodroski JG, Sundquist WI, Yeager M: Hexagonal assembly of a restricting TRIM5alpha protein. Proc Natl Acad Sci U S A. 2011, 108: 534-539. 10.1073/pnas.1013426108.PubMed CentralView ArticlePubMedGoogle Scholar
- Nisole S, Lynch C, Stoye JP, Yap MW: A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1. Proc Natl Acad Sci U S A. 2004, 101: 13324-13328. 10.1073/pnas.0404640101.PubMed CentralView ArticlePubMedGoogle Scholar
- Sayah DM, Sokolskaja E, Berthoux L, Luban J: Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature. 2004, 430: 569-573. 10.1038/nature02777.View ArticlePubMedGoogle Scholar
- Dudding LR, Nkabinde NC, Mizrahi V: Analysis of the RNA- and DNA-dependent DNA polymerase activities of point mutants of HIV-1 reverse transcriptase lacking ribonuclease H activity. Biochemistry. 1991, 30: 10498-10506. 10.1021/bi00107a019.View ArticlePubMedGoogle Scholar
- Shi J, Zhou J, Shah VB, Aiken C, Whitby K: Small-molecule inhibition of human immunodeficiency virus type 1 infection by virus capsid destabilization. J Virol. 2011, 85: 542-549. 10.1128/JVI.01406-10.PubMed CentralView ArticlePubMedGoogle Scholar
- Jun S, Ke D, Debiec K, Zhao G, Meng X, Ambrose Z, Gibson GA, Watkins SC, Zhang P: Direct visualization of HIV-1 infection using correlative live-cell microscopy and cryo-electron microscopy. Structure. 2011, 19: 1573-1581. 10.1016/j.str.2011.09.006.PubMed CentralView ArticlePubMedGoogle Scholar
- Yang R, Shi J, Byeon IJ, Ahn J, Sheehan JH, Meiler J, Gronenborn AM, Aiken C: Second-site suppressors of HIV-1 capsid mutations: restoration of intracellular activities without correction of intrinsic capsid stability defects. Retrovirology. 2012, 9: 30-10.1186/1742-4690-9-30.PubMed CentralView ArticlePubMedGoogle Scholar
- Blair WS, Pickford C, Irving SL, Brown DG, Anderson M, Bazin R, Cao J, Ciaramella G, Isaacson J, Jackson L, et al: HIV capsid is a tractable target for small molecule therapeutic intervention. PLoS Pathog. 2010, 6: e1001220-10.1371/journal.ppat.1001220.PubMed CentralView ArticlePubMedGoogle Scholar
- von Schwedler UK, Stray KM, Garrus JE, Sundquist WI: Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J Virol. 2003, 77: 5439-5450. 10.1128/JVI.77.9.5439-5450.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Yap MW, Dodding MP, Stoye JP: Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. J Virol. 2006, 80: 4061-4067. 10.1128/JVI.80.8.4061-4067.2006.PubMed CentralView ArticlePubMedGoogle Scholar
- Mirambeau G, Lyonnais S, Gorelick RJ: Features, processing states, and heterologous protein interactions in the modulation of the retroviral nucleocapsid protein function. RNA Biol. 2010, 7: 724-734. 10.4161/rna.7.6.13777.PubMed CentralView ArticlePubMedGoogle Scholar
- Kutluay SB, Perez-Caballero D, Bieniasz PD: Fates of retroviral core components during unrestricted and TRIM5-restricted infection. PLoS Pathog. 2013, 9: e1003214-10.1371/journal.ppat.1003214.PubMed CentralView ArticlePubMedGoogle Scholar
- Shah VB, Shi J, Hout DR, Oztop I, Krishnan L, Ahn J, Shotwell MS, Engelman A, Aiken C: The host proteins transportin SR2/TNPO3 and cyclophilin A exert opposing effects on HIV-1 uncoating. J Virol. 2013, 87: 422-432. 10.1128/JVI.07177-11.PubMed CentralView ArticlePubMedGoogle Scholar
- Wu X, Liu H, Xiao H, Conway JA, Hunter E, Kappes JC: Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J. 1997, 16: 5113-5122. 10.1093/emboj/16.16.5113.PubMed CentralView ArticlePubMedGoogle Scholar
- Cecilia D, KewalRamani VN, O'Leary J, Volsky B, Nyambi P, Burda S, Xu S, Littman DR, Zolla-Pazner S: Neutralization profiles of primary human immunodeficiency virus type 1 isolates in the context of coreceptor usage. J Virol. 1998, 72: 6988-6996.PubMed CentralPubMedGoogle Scholar
- Bartz SR, Vodicka MA: Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. Methods (San Diego, Calif). 1997, 12: 337-342. 10.1006/meth.1997.0487.View ArticleGoogle Scholar
- Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK: A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci U S A. 2004, 101: 5652-5657. 10.1073/pnas.0400830101.PubMed CentralView ArticlePubMedGoogle Scholar
- Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ: Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol. 1995, 69: 4582-4586.PubMed CentralPubMedGoogle Scholar
- Zhang YJ, Hatziioannou T, Zang T, Braaten D, Luban J, Goff SP, Bieniasz PD: Envelope-dependent, cyclophilin-independent effects of glycosaminoglycans on human immunodeficiency virus type 1 attachment and infection. J Virol. 2002, 76: 6332-6343. 10.1128/JVI.76.12.6332-6343.2002.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.